Press releaseGlobe Newswire
CalciMedica
CALC · NASDAQ
$1.07+$0.045 (+4.41%)TodayMarket closed ·
Prev close $1.02
Latest news
- Press releaseGlobe Newswire
CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releasePRNewswire
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsVandana Singh
FDA Raises No Concerns Over Auxora Safety Data, CalciMedica Advances Trial
- News
Market-Moving News for June 24th
- Press releasePRNewswire
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
- Press releasePRNewswire
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
- News
CalciMedica Q1 EPS $0.30 Beats $(0.28) Estimate
- Press releasePRNewswire
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- Press releasePRNewswire
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsAvi Kapoor
Gold Jumps Over 4%; Seagate Shares Gain After Q2 Results
- NewsAvi Kapoor
Nasdaq Gains 150 Points; Starbucks Shares Rise After Strong Sales
- Press releasePRNewswire
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
- Press releasePRNewswire
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
- Press releasePRNewswire
CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension
- Press releasePRNewswire
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
- Press releasePRNewswire
CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™
- Press releasePRNewswire
CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
- Press releasePRNewswire
CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releasePRNewswire
CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
- Press releasePRNewswire
CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure
- Press releasePRNewswire
CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting
- Press releasePRNewswire
CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
- Press releasePRNewswire
CalciMedica Announces Presentations at Upcoming Medical Meetings
- Press releasePRNewswire
CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference
- Press releasePRNewswire
CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates
- Press releasePRNewswire
CalciMedica Secures Credit Facility for Up to $32.5 Million
- Press releasePRNewswire
CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference
- Press releasePRNewswire
CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.